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Abstract 
Purpose: To describe the clinical signs of gelatinous drop-like corneal dystrophy 
(GDCD) in a consanguineous Colombian family and determine the underlying 
genetic cause. 
Methods: We performed ocular examination of available family members and bi-
directionally Sanger sequenced the GDCD-associated gene, TACSTD2. In one 
individual, the presence of subepithelial amyloid was confirmed with biopsy.  
Results: The parents were consanguineous and five of their ten children had 
GDCD. Typical mulberry subepithelial deposits with subepithelial vascularization 
were present in 3 individuals; 2 individuals only had mild polymorphic anterior 
stromal opacity. We identified a homozygous TACSTD2 missense mutation, 
c.551A>G, p.(Tyr184Cys), in affected family members. Both parents were 
heterozygous for the mutation, and unaffected siblings were either heterozygous or 
homozygous wild-type for this allele. In the Colombian population this mutation has 
a minor allele frequency (MAF) of 0.53%. 
Conclusion: The clinical presentation of GDCD in this family was variable and 
does not solely support an age dependent progression of the phenotype, 
suggesting that environmental or other genetic factors can modify phenotypic 
expression. The relatively high prevalence of this mutation in the Colombian 
population suggests that other individuals may have undiagnosed subclinical 
disease. 
 
Key words: Gelatinous drop-like corneal dystrophy, primary familial amyloidosis of 
the cornea, hereditary corneal dystrophies, corneal amyloidosis. 	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Introduction 
Gelatinous drop-like corneal dystrophy (GDCD; MIM 204870) was first described in 
Japanese patients in 1914.1 It is a rare autosomal recessive disease with features 
consistent with bilateral corneal amyloidosis, leading to pain and severe loss of 
sight.2, 3 The majority of reports are from Japan, where the prevalence is estimated 
to be 1:300,000 individuals.4 The first case report from outside Japan was from the 
United States where it was termed primary familial amyloidosis of the cornea.5 In 
Latin America, clinical reports of GDCD cases have been described from Mexico, 
with 13 cases observed over a 44 year period, and a single case from Brazil.6-8 
 
The phenotype of GDCD can gradually develop over time. In the first decade there 
may only be subepithelial lesions that are similar to band-shaped corneal 
degeneration, or multiple small grayish epithelial nodules that cause severe 
photophobia, tearing and foreign body sensation. Over time the nodules increase 
in number and coalesce to give a mulberry appearance. Finally, in the third decade 
there is secondary stromal opacification and neovascularization with severe visual 
loss.9-11 The histopathological features include subepithelial and anterior stromal 
amyloid material deposit with loss of the Bowman layer. The amyloid deposits stain 
with Congo red, and show birefringence and dichroism under polarized light.12 
Physiologically, there is increased permeability of the epithelial cell junction.13 Bi-
allelic mutations in TACSTD2 (previously M1S1 or TROP2), located on 
chromosome 1p32 cause GDCD (MIM 137290).14 TACSTD2 encodes tumor 
associated calcium signal-transducer 2 protein that, in association with claudins 1 
and 7, functions as a transmembrane glycoprotein to maintain the corneal epithelial 
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barrier. Loss of this barrier function is associated with accumulation of amyloid in 
the cornea.15 
 
The purpose of this study is to report the clinical features of a consanguineous 
family with GDCD from Colombia and establish the genetic cause of disease.  
 
MATERIALS AND METHODS 
All participants or their parents provided informed consent for this study. The 
research was approved by the Ethics Committee of the Medical Research Institute 
of the University of Antioquia, and adhered to the tenets of the Declaration of 
Helsinki. A consanguineous family affected with GDCD was examined (Figure 1). A 
family history and pedigree was constructed and a clinical ophthalmological 
examination was performed. A therapeutic superficial keratectomy was performed 
for one patient (individual II:10) and the material was processed for histology. A 
10ml peripheral venous blood sample was taken and DNA extracted (DNeasy, 
Qiagen®).   
 
The single coding exon of TACSTD2 was amplified by PCR using KapaRobust TM 
polymerase (Kapa Biosystems) with primers F: 5'-CCTGCAGACCATCCCAGAC-3' 
and R: 5'-CAGGAAGCGTGACTCACTTG-3'.14 PCR products were purified using a 
MultiScreen® PCRµ96 plate (Millipore) and bi-directionally Sanger sequenced.  
Sequences were aligned and compared to the reference sequence using DNAstar 
package software version 8.0.2 (Lasergene). Variants were annotated in 
accordance with Ensembl transcript ID ENST00000371225. 
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Two different bioinformatics tools were applied to predict the effect of amino acid 
substitution on TACSTD2 function: SIFT (v4.0.3; http://sift.jcvi.org/)16, which uses 
sequence homology to make predictions and PolyPhen-2 (v2.0.23; 
http://genetics.bwh.harvard.edu/pph2/)17, which uses both sequence-based and 
structure-based predictive features. TACSTD2 variants were checked for their 
frequency in the Exome Aggregation Consortium database 
(http://exac.broadinstitute.org/about ) which includes exome data from 63,358 
individuals of varying ethnicity.   
 
RESULTS  
The family consisted of consanguineous parents from Caldas in Colombia (Figure 
1). The parents had a normal ophthalmic examination. The couple had ten male 
children, of whom II:1 and II:2 were unavailable for evaluation but had no reported 
ophthalmic symptoms. Individuals II:6, II:7 and II:11 were clinically unaffected. A 
maternal uncle was reported to have died blind with opaque corneas of unknown 
etiology. The son of II:3 (III:1) had no ophthalmic symptoms. Patient II:5 had a well-
differentiated rectal mucinous adenocarcinoma diagnosed at age 22 years, but no 
other extra-ocular phenotype was noted in any patient. 
 
Clinical findings 
All affected individuals had photophobia, foreign body sensation and blurred vision. 
There was a significant variation in the phenotype between affected individuals. 
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The proband (II: 10) had photophobia and ocular discomfort since the first year of 
life. Corneal opacities were noted at three years of age, with a visual acuity of 
count fingers right eye and light perception left eye. By age ten there were dense 
central corneal opacities with an irregular friable surface with circumferential 
superficial and deep corneal vascularization (Figure 2A). He had a left superficial 
keratotomy with an amniotic membrane onlay graft and temporal tarsorrhaphy. 
After 6 months the visual acuity had improved to 20/200 right eye and 20/400 left 
eye, with a reduction in opacity (Figure 2B). Histopathology of the excised material 
showed a stratified squamous corneal epithelium, with preserved polarity and 
maturation, but with diffuse deposition of an amorphous eosinophilic material in the 
stroma consistent with amyloid (Supplementary Figure 1). A similar mulberry 
appearance with neovascularization was noted in individuals II:3 aged 25 years 
(VA 20/100 BE) and II:5 aged 23 years (VA count fingers OD and hand movements 
OS) (Figure 2E and 2F). However, in individuals II:8 and II:9 aged 14 and 11 years 
the visual acuity was preserved (II:8 20/30 OD, 20/25 OS; II:9 20/20 BE). In both 
these individuals the corneal changes were less severe with only polymorphic grey 
subepithelial band-shaped opacities without neovascularization, with late epithelial 
stain following instillation of fluorescein (Figure 2D and 2E). In addition, two 
affected individuals (II:3 and II:8) also showed peri-limbal deposits suggestive of 
amyloid material (Figure 2F) 
 
Genetic analysis of TACSTD2  
Screening the TACSTD2 gene identified a single variant; c.551A>G, p.(Y184C) 
(rs190800473),  which fully segregated with the disease in the family. All affected 
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individuals were homozygous for the mutation, both unaffected parents (I:1 and 
I:2), one healthy sibling (II:7) and the son of affected individual II:3 (III:1)  were 
heterozygous for the mutation.   All remaining unaffected family members were 
Homozygous wild-type (Figure 1).  
 
The same mutation has previously been identified in a compound heterozygous 
state in an affected individual in combination with the Japanese founder mutation 
c.352C>T, p.(Q118X), and is therefore considered to be disease-causing 18. This is 
the first report of the mutation in the homozygous state.  The TACSTD2 gene is 
present only in mammals and birds. The non-synonymous variant, p.(Y184C), 
alters a highly conserved residue (Supplementary Figure 2). Using SIFT and 
Polyphen2 prediction tools, the p.(Y184C) substitution is predicted to be Damaging 
(0) and Probably Damaging (0.994), respectively.  
 
The variant was identified only once in the heterozygous state out of 107098 
alleles in the Exome Aggregation Consortium (ExAC) database, thus this variant is 
extremely rare (MAF = 0.000009337). The ExAC data set combines exome 
sequencing data from large-scale sequencing projects world-wide; the single 
occurrence of the mutation was detected in an individual of Colombian origin 
sequenced as part of the 1000 Genomes Project. In total,  93 Colombian 
individuals were sequenced, therefore the variant has a MAF of  0.53% in this 
specific population.  
 
DISCUSSION 
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This is the first time, to our knowledge, that GDCD has been genetically solved in 
patients of Latin American origin (Table 2). The causative homozygous TACSTD2 
mutation identified in all affected family members has only previously been 
identified in the compound heterozygous state in a Chinese patient. 18   
The identification of five affected individuals in this consanguineous family helps to 
define the phenotypic spectrum associated with the p.(Y184C) TACSTD2 mutation, 
which shows clinical variability between affected individuals.  Two affected 
individuals (II:8 and II:9), age 14 and 11 years, had a mild phenotype with an 
appearance similar to band-shaped keratopathy, characteristic of early GDCD. 11, 13 
The remaining three affected family members (II:3, II:5 and II:10), age 25, 23 and 
10 years, had a more characteristic phenotype with a mulberry appearance and 
secondary stromal neovascularization of the cornea, associated with severe 
photophobia, discomfort and blindness. These differences suggest that 
environmental or other genetic factors contribute to the phenotype, although it is 
possible that the milder phenotype observed in some individuals in this family could 
progress over time. Previous reports have indicated that the phenotypic variability 
for this dystrophy is due to age related progression over time, as the nodular 
subepithelial amyloid deposits gradually increase in number and coalesce during 
the first and second decades of life.3, 9, 10 Two affected individuals (II:3 and II:8) 
also showed peri-limbal deposits suggestive of amyloid material, although 
confirmation would require a histopathological examination.19 
 
GDCD is normally associated with severe ocular morbidity and blindness. Visual 
rehabilitation is problematic, often requiring multiple surgical interventions, with a 
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high rate of recurrence and continued visual decline. After superficial excision of 
affected material, lamellar or penetrating keratoplasty, temporary improvement can 
be achieved, but with recurrence at an average of 26 months.20, 21 Individual II:10 
had a superficial keratotomy with an amniotic membrane graft that improved the 
visual acuity and gave a marked reduction in symptoms for six months, but further 
follow up is required to confirm the duration of this effect. 
 
Although most reports of GDCD are from East Asia, cases have also been 
reported from other regions.5 To date, 28 different disease-causing mutations in 
the TACSTD2 gene have been reported, shown in Table 1 with the ethnicity of the 
affected patients. The majority of mutations are predicted to produce truncated 
proteins, or proteins degraded by nonsense mediated decay, because of 
nucleotide substitutions that generate premature stop codons. The remainder are 
missense changes of conserved residues. The most frequently reported mutation 
is the c.352C>T, p.(Q118X) mutation which is a founder mutation in the Japanese 
population, explaining the higher prevalence of GDCD in Japan.14 
 
Figure 3 shows a schematic representation of pathogenic TACSTD2 mutations, 
including the p.(Y184C) mutation, and their location in regards to the functional 
domains of the TACSTD2 protein. Given the range of previously described 
missense mutations (see Table 1), it is noteworthy that cysteine residues are often 
eliminated or created, which might point to a common mechanism of disruption of 
disulphide bonds in the extracellular domain of the protein. In the cornea, 
TACSTD2 is localized to epithelial cell junctions and reduction of TACSTD2 
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expression has been shown to lead to altered expression and modification of 
intercellular proteins, including claudins 1, 4, and 7, ZO1 and occludin.15 This 
impairs the function of the epithelial barrier, allowing the formation of amyloid 
deposits of lactoferrin, apolipoprotein and transforming growth factor β (TGFBI). 
23,24
 There is evidence that amyloid fibers are formed by non-enzymatic post-
translational modifications of these proteins, including the formation of advanced 
glycation end products (AGE) and the racemization of aspartyl residues that lead to 
the misfolding of DNA, resistance to degradation and posterior accumulation.24 
 
 A single heterozygous carrier of the p.(Y184C) mutation was identified in the 1000 
Genomes Project which includes exome sequence data for  93 unrelated 
individuals from Colombia, suggesting a  0.53% frequency for the allele in this 
population.  Based on this allele frequency, and excluding inbreeding, we 
estimated the prevalence of GDCD to be 1:35,714  in Colombia, which is 8,5 times 
the prevalence of GDCD in the Japanese population, for which a founder effect for 
the p.(Q118X) mutation has been reported. The family is originally from a village in 
the Department of Caldas in Colombia that has had a rapid expansion in 
population since its founding.25 
 
This is the first clinical, genetic and histopathological description of GDCD from 
Colombia. The clinical variability of the corneal changes in the affected family 
members helps define the phenotype of this disease. The most severely affected 
individual (II:5; 23 years of age) had a history of a colon adenocarcinoma. Although 
this association has not been highlighted in other reports, a higher expression of 
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TACSTD2 has been reported to be associated with aggressive colorectal 
carcinoma.26 It is noteworthy that the relatively high frequency of this allele in 
ethnically matched control subjects predicts a higher frequency of the disease in 
Colombia than has been reported in the Japanese population.  
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Figures 
Figure 1. Pedigree of a Colombian family with GDCD and segregation of a 
homozygous TACSTD2 missense mutation. The closed symbols represent the 
individuals diagnosed with GDCD, open symbols are unaffected. The proband 
(II:10) is marked with an arrow. The letters A and G represent the genotypes for 
each individual on the complementary strand; A is the wild type allele and G is the 
mutated allele. * indicates patient has been clinically examined and a DNA sample 
obtained.  No DNA sample was available for patients II:1 and II:2. Individuals II:3, 
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II:5 and II:10 had a severe phenotype (shown in black), while II:8 and II:9 had a 
milder phenotype with preserved vision (shown in grey). 
 
Figure 2. Differential phenotypic expression of GDCD in affected individuals. 
(A) Individual II:10 aged 10 years (right eye) with a typical mulberry corneal lesion 
with superficial vascularization, and (B) (left eye) 6 months after the superficial 
keratectomy. (C) Individual II:5 aged 23 years (right eye) showing mainly peripheral 
lesions, some of which are raised with a mulberry appearance accompanied by 
extensive superficial vascularization. (D) Individual II:8 aged 14 years (left eye) and 
(E) (right eye) with grey central and paracentral subepithelial band-shaped 
opacities. (F) Individual II:3 aged 25 years (right eye) with polymorphic white-
yellowish subepithelial corneal and conjunctival lesions with a mulberry 
appearance and extensive superficial vascularization. 
 
Figure 3. Topology diagram showing location of pathogenic TACSTD2 
mutations. Amino acids are numbered at 50 residue intervals. Intracellular, 
cytosolic and extracellular aspects of the protein are shown, with functional 
domains and residues (glycosylation sites and disulphide residues) highlighted. All 
published mutations are mapped to the protein, coloured for functional 
consequences: missense (yellow), frameshift (grey) and stop (red) mutations.  
 
Supplementary Figure 1. Corneal histology for Individual II:10. (A): Diffuse 
deposition of amorphous eosinophilic material beneath the epithelium  
(hematoxylin-eosin). (B) Positive staining for subepithelial amyloid material (Congo 
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red). 
 
Supplementary Figure 2. Alignment of p.Tyr184 residue showing 
conservation. Alignment of vertebrate TACSTD2 sequences using ClustalW 
shows conservation of the tyrosine residue shown in bold.   
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